POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on January 31, 2024, 09:03:41 am
-
A small study indicates DTG + 2x NRTI is successful at suppressing HIV 2.
In Brief:
Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 NRTI HIV Type 2. Results From a 48-Week Phase 2 Study
We conducted a phase 2, single-arm, open-label trial to evaluate the safety and efficacy of a triple therapy regimen that included DTG in persons with HIV-2 (PWHIV-2) in Portugal.
Results
A total of 30 patients were enrolled (22 women; median age, 55 years). Three patients discontinued the study. At week 48, all participants (27) had pVL <40 copies/mL. No virological failures were observed.
Conclusions
DTG plus 2 NRTIs is safe and effective as first-line treatment for PWHIV-2 with a tolerability profile previously known.
Study publication:
Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study, Clinical Infectious Diseases, Volume 77, Issue 5, 1 September 2023, Pages 740–748 https://doi.org/10.1093/cid/ciad339
Aidsmap article: https://www.aidsmap.com/news/jan-2024/dolutegravir-based-triple-therapy-effectively-suppresses-hiv-2-viral-load-small-study